Opportunities to exploit non-neutralizing HIV-specific antibody activity.
about
NK Cells in HIV DiseaseMechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome VirusWhich Antibody Functions are Important for an HIV Vaccine?Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.The dysfunction of T follicular helper cellsModeling mucosal cell-associated HIV type 1 transmission in vitro.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Mucosal Immunogenicity of Genetically Modified Lactobacillus acidophilus Expressing an HIV-1 Epitope within the Surface Layer Protein.HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humansProtective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.Highly individual patterns of virus-immune IgG effector responses in humans.A Functional Role for Antibodies in Tuberculosis.HIV: Potency needs constancy.Highly parallel characterization of IgG Fc binding interactions.IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.Sex Differences in HIV Infection: Mystique Versus Machismo
P2860
Q26752833-2F3A121C-87FE-43C1-B142-5948758C1EFDQ32183108-003AF1B3-F197-4850-BF28-10E2881B6EC4Q33772637-2EF2EB6E-78B0-4033-BB34-6F7F45C8AA49Q33851717-3E80EC73-5F88-49FF-B41F-B2D491B379DCQ34252448-04D5976E-E7CB-4314-B580-7C81702FA9DBQ35000072-E833F169-79E8-4420-B2F2-37A162F29B20Q35569901-0B6BC776-5E91-4D08-9CC5-E752E6C6991EQ35824311-18823780-19EE-424B-BF86-4FF11A4C1C14Q36252656-9B00A5B3-0E5B-4798-A980-620C78EFFA52Q36300153-ADC45490-A95E-44D3-8941-BAA31302152EQ36481483-95483C7D-54AE-446E-B562-2BB4A1E0CE66Q38727815-FAD2901E-1AE7-4D0B-AD04-3064ED8FC148Q38953491-094F2ED3-F47A-4493-942B-15EA0886BF21Q39352413-A7A31E14-FE9F-4924-AC7B-09870FDA3EAEQ41690058-55364204-6961-44F7-8266-49A957833EF8Q42909129-2584B575-6898-493C-9C84-B7F7A8DF8D08Q52590766-8E17C3F3-0196-46DD-8B85-339841865144Q56996082-0E95F0F6-7D95-4375-A5A6-46DB6357AD49
P2860
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
@en
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
@nl
type
label
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
@en
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
@nl
prefLabel
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
@en
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
@nl
P2860
P1433
P1476
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
@en
P2093
Galit Alter
Margaret E Ackerman
P2860
P304
P356
10.2174/1570162X113116660058
P577
2013-07-01T00:00:00Z